Will Robberts News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Will robberts. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Will Robberts Today - Breaking & Trending Today
Share this article Share this article MENLO PARK, Calif., May 13, 2021 /PRNewswire/ LIPAC Oncology LLC., a pharmaceutical company utilizing its liposome-bound nano-technology platform to provide precision targeted cancer drugs for the treatment of multiple tumor types, today announced the appointment of Daniel K. Spiegelman as an independent board advisor. We are excited to welcome Dan as an advisor, said Will Robberts, President of LIPAC Oncology. With more than 30 years of biotechnology industry experience and proven expertise in finance, business development and value creation for clinical and commercial stage companies, we look forward to his insights as we advance our oncology pipeline. ....
LIPAC Oncology Announces Appointment of Josh Hamermesh to the Board of Directors Industry Veteran Brings More Than 20 Years of Biotech Leadership Experience News provided by Share this article Share this article MENLO PARK, Calif., May 6, 2021 /PRNewswire/ LIPAC Oncology LLC., a pharmaceutical company utilizing its liposome-bound nano-technology platform to provide precision targeted cancer drugs for the treatment of multiple tumor types, today announced the appointment of Josh Hamermesh as an independent board director. Josh is a noted expert in driving and supporting the growth of innovative companies thanks to his two decades of leadership experience in the biotechnology industry, said Will Robberts, President of LIPAC Oncology. We welcome Josh to the Board and look forward to his insights and contributions around both corporate and business development, strategy and commercialization as we continue to advance our oncology pipeline and build our bu ....
Share this article Share this article MENLO PARK, Calif., April 29, 2021 /PRNewswire/ LIPAC Oncology LLC today announced the conclusion of a successful Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss Phase 2b/3 clinical trials of LiPax in patients with low-grade highly recurrent non-muscle invasive bladder cancer (NMIBC). The feedback from the FDA provides a clear path for LIPAC Oncology to initiate the Phase 2b trial for LiPax in the second half of 2021. We appreciate the thoughtful feedback and guidance from the FDA and acceptance of our proposed design for the Phase 2b/3 trial of LiPax, said Michael Oefelein, M.D., Chief Medical Officer of LIPAC Oncology. Non-muscle invasive bladder cancer is difficult to treat and highly recurrent. With the lack of existing treatment options for low to intermediate risk NMIBC, the unmet medical need is very high. ....
LIPAC Oncology Announces Successful Type B Meeting with the U.S. FDA for the Study of LiPax for Non-Muscle Invasive Bladder Cancer prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.